Difference between revisions of "OSTEOPOROSIS-MANAGEMENT"
(Imported from text file) |
(Imported from text file) |
||
| Line 8: | Line 8: | ||
<br/> | <br/> | ||
<br/><i>PHARMACOLOGIC MANAGEMENT</i> | <br/><i>PHARMACOLOGIC MANAGEMENT</i> | ||
<br/>1. Calcium | <br/>1. Calcium supplementation | ||
<br/>2. Vitamin D | |||
<br/> | |||
<br/>3. Bisphosphonates: oral bisphosphonates are first line | <br/>3. Bisphosphonates: oral bisphosphonates are first line | ||
<br/>4. Denosumab | <br/>4. Denosumab | ||
Latest revision as of 02:29, 21 March 2023
SUMMARY
NON-PHARMACOLOGIC MANAGEMENT
1. Weight-bearing exercises, gait & balance training
2. Diet high in calcium
3. Sunlight exposeure for Vitamin D
4. Maintenance of good BMI
5. Avoiding cigarette smoking & excessive alcohol intake
PHARMACOLOGIC MANAGEMENT
1. Calcium supplementation
2. Vitamin D
3. Bisphosphonates: oral bisphosphonates are first line
4. Denosumab
5. Estrogen +/- Progesterone: in post-menopausal women
6. Selective Estrogen Receptor Modulators (SERM): for those who are unable to take estrogen (breast cancer risk)
7. Calcitonin
8. Teriparatide
9. Romosozumab
10. Management of secondary osteoporosis: management of hypogonadism in men with testosterone, etc.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
